Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Inhibikase Therapeutics's price to book ratio was 1.4× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 0.2× to 3.6×, with a median of 1.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.4× | −0.7 |
| 2025 | Dec 31, 2025 | 2.1× | −1.5 |
| 2024 | Oct 31, 2024 | 3.6× | +3.1 |
| 2023 | Dec 29, 2023 | 0.5× | −0.0 |
| 2022 | Dec 30, 2022 | 0.5× | −0.3 |
| 2021 | Dec 31, 2021 | 0.8× | – |
See a number that looks wrong?